Proteostasis Therapeutics (PTI) PT Lowered to $4 at Cantor Fitzgerald, Remains 'Overweight'
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska lowered the price target on Proteostasis Therapeutics (NASDAQ: PTI) to $4.00 (from $8.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
